심방세동 시장 규모, 점유율, 성장 및 세계 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of atrial fibrillation Market

The global atrial fibrillation market was valued at USD 17.24 billion in 2025 and is projected to grow from USD 17.24 billion in 2026 to USD 25.75 billion by 2034, registering a CAGR of 4.59% during the forecast period (2026-2034). North America dominated the global market with a 38.33% market share in 2025, driven by the high prevalence of cardiovascular diseases, favorable reimbursement policies, strong pharmaceutical research, and continuous introduction of innovative therapies.

Atrial fibrillation (AFib) is one of the most common cardiac arrhythmias characterized by an irregular and often rapid heartbeat, increasing the risk of stroke, heart failure, and other cardiovascular complications. The condition is becoming increasingly prevalent due to aging populations, obesity, hypertension, diabetes, and sedentary lifestyles. As awareness regarding early diagnosis and treatment grows, healthcare providers are increasingly adopting advanced anticoagulants and antiarrhythmic drugs to improve patient outcomes. Furthermore, government healthcare initiatives, expanding clinical research, and the development of novel therapies are expected to support steady market growth through 2034.

Market Drivers

One of the primary drivers of the atrial fibrillation market is the growing burden of cardiovascular diseases and the expanding elderly population worldwide. According to the World Health Organization, hypertension affects more than 1.28 billion adults globally, significantly increasing the risk of atrial fibrillation. In addition, the rising incidence of obesity, diabetes, smoking, and other lifestyle-related disorders continues to increase the patient population requiring long-term AFib management.

The market is also benefiting from increasing investments in innovative drug development. Pharmaceutical companies are actively developing next-generation anticoagulants and monoclonal antibodies designed to improve efficacy while minimizing bleeding risks. Regulatory agencies are further accelerating product approvals to expand treatment options for patients.

Market Trends

A major trend shaping the market is the growing focus on novel anticoagulant therapies and monoclonal antibodies. Companies are investing heavily in Factor XI/XIa inhibitors and other innovative treatments that offer improved safety profiles compared to conventional anticoagulants.

Another significant trend is the increasing adoption of Direct Oral Anticoagulants (DOACs), which provide effective stroke prevention while offering greater convenience than traditional therapies. Rising clinical trials, strategic collaborations, and continuous product innovations are expected to strengthen the competitive landscape during the forecast period.

Market Restraints

Despite favorable growth prospects, several challenges continue to restrain market expansion. Frequent product recalls due to manufacturing issues, labeling errors, and quality concerns may negatively affect physician confidence and patient adoption.

Additionally, alternative treatment options such as catheter ablation, left atrial appendage closure procedures, and other minimally invasive interventions provide competition for pharmacological therapies, limiting the overall growth potential of the drug market.

Market Segmentation

By Drug Class

The anticoagulants segment is expected to dominate the global market with a 78.92% share in 2026. Increasing government recommendations supporting anticoagulant use for stroke prevention, coupled with growing approvals of Direct Oral Anticoagulants (DOACs), continue to strengthen this segment. Meanwhile, the antiarrhythmic drugs segment is also witnessing steady growth owing to ongoing clinical development and new drug approvals.

By Route of Administration

The oral segment is projected to account for 84.98% of the global market in 2026. The widespread availability of oral medications, improved patient compliance, and increasing adoption of oral anticoagulants are driving segment growth. The intravenous segment continues to serve emergency treatment settings but represents a comparatively smaller share.

By Distribution Channel

Retail pharmacies are expected to lead the distribution landscape with a 48.03% market share in 2026 due to their broad accessibility, consumer convenience, and expanding pharmacy networks. Online pharmacies are also gaining popularity as patients increasingly prefer home delivery services and discounted medication pricing.

Regional Insights

North America remained the leading regional market, generating USD 6.61 billion in 2025, and is expected to reach USD 6.85 billion in 2026. Strong healthcare infrastructure, increasing prevalence of atrial fibrillation, active clinical research, and frequent regulatory approvals continue to support regional dominance. The U.S. market is projected to reach USD 6.14 billion in 2026.

Europe accounted for USD 4.49 billion in 2025 and is projected to reach USD 4.72 billion in 2026. Market growth is supported by increasing cardiovascular disease prevalence, expanding geriatric population, and significant investments in cardiovascular drug development.

Asia Pacific generated USD 3.46 billion in 2025 and is expected to grow to USD 3.68 billion in 2026. Rising awareness, growing healthcare expenditure, increasing elderly populations, and expanding access to advanced cardiovascular treatments continue to accelerate regional market growth.

Latin America and the Middle East & Africa are also witnessing steady expansion due to improving healthcare infrastructure, greater awareness regarding AFib management, and rising cardiovascular disease incidence.

Competitive Landscape

The atrial fibrillation market is moderately consolidated, with major pharmaceutical companies focusing on expanding product portfolios through clinical research, strategic collaborations, and geographic expansion. Leading market participants include Bristol-Myers Squibb Company, Bayer AG, Daiichi Sankyo, Sanofi, Johnson & Johnson, Pfizer Inc., Eisai Co., Ltd., and Par Pharmaceutical. Continuous investment in innovative anticoagulants and next-generation cardiovascular therapies is expected to intensify competition throughout the forecast period.

Recent Industry Developments

• In November 2023, Bayer AG expanded its Phase III clinical trials for asundexian, targeting stroke prevention in atrial fibrillation patients.
• In March 2023, Bristol Myers Squibb and Janssen Pharmaceuticals initiated the Phase III Librexia trial to evaluate Milvexian for stroke prevention.
• In July 2022, InCarda Therapeutics enrolled the first patient in its pivotal Restore-1 Phase III clinical trial for InRhythm.
• In June 2022, Apotex launched the generic anticoagulant APO-Apixaban in Canada.
• In June 2019, TOA EIYO Ltd. and Astellas Pharma introduced Bisono Tape 2 mg, a B1-blocker transdermal patch for atrial fibrillation treatment in Japan.

Conclusion

The global atrial fibrillation market is expected to witness steady growth through 2034, supported by the increasing prevalence of cardiovascular diseases, expanding geriatric population, and rising demand for advanced anticoagulant therapies. Continuous innovation in drug development, favorable regulatory support, growing awareness regarding stroke prevention, and expanding healthcare access are expected to create significant opportunities for pharmaceutical companies. Despite challenges such as product recalls and competition from interventional treatment options, the market is well-positioned for sustained long-term growth as healthcare systems increasingly prioritize effective atrial fibrillation management.

Segmentation By Drug Class

• Anticoagulants
• Antiarrhythmic Drugs

By Route of Administration

• Oral
• Intravenous
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region

• North America (By Drug Class, Route of Administration, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence/Incidence of Arrhythmia, Key Region, 2024/2025
• 4.2. Key Industry Developments - Mergers, Partnerships, Acquisitions
• 4.3. New Product Launches by Key Players
• 4.4. Impact of COVID-19 on Atrial Fibrillation Market

5. Global Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Anticoagulants
  • 5.1.2. Anti-arrhythmic Drugs
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Intravenous
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Online Pharmacies
  • 5.3.3. Retail Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Anticoagulants
  • 6.1.2. Anti-arrhythmic Drugs
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Intravenous
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Online Pharmacies
  • 6.3.3. Retail Pharmacies
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Drug Class
  • 6.4.2. Canada
    • 6.4.2.1. By Drug Class

7. Europe Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Anticoagulants
  • 7.1.2. Anti-arrhythmic Drugs
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Intravenous
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Online Pharmacies
  • 7.3.3. Retail Pharmacies
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. Germany
    • 7.4.1.1. By Drug Class
  • 7.4.2. U.K.
    • 7.4.2.1. By Drug Class
  • 7.4.3. France
    • 7.4.3.1. By Drug Class
  • 7.4.4. Spain
    • 7.4.4.1. By Drug Class
  • 7.4.5. Italy
    • 7.4.5.1. By Drug Class
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Drug Class
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Drug Class

8. Asia Pacific Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Anticoagulants
  • 8.1.2. Anti-arrhythmic Drugs
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Intravenous
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Online Pharmacies
  • 8.3.3. Retail Pharmacies
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. Japan
    • 8.4.1.1. By Drug Class
  • 8.4.2. China
    • 8.4.2.1. By Drug Class
  • 8.4.3. India
    • 8.4.3.1. By Drug Class
  • 8.4.4. Australia
    • 8.4.4.1. By Drug Class
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Drug Class
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Drug Class

9. Latin America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Anticoagulants
  • 9.1.2. Anti-arrhythmic Drugs
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Intravenous
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Online Pharmacies
  • 9.3.3. Retail Pharmacies
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Drug Class
  • 9.4.2. Mexico
    • 9.4.2.1. By Drug Class
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Drug Class

10. Middle East & Africa Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Anticoagulants
  • 10.1.2. Anti-arrhythmic Drugs
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Oral
  • 10.2.2. Intravenous
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Online Pharmacies
  • 10.3.3. Retail Pharmacies
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.4.1. GCC
    • 10.4.1.1. By Drug Class
  • 10.4.2. South Africa
    • 10.4.2.1. By Drug Class
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Drug Class

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Bristol-Myers Squibb Company
    • 11.2.1.1. Overview
    • 11.2.1.2. Product
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. Sanofi
    • 11.2.2.1. Overview
    • 11.2.2.2. Product
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Eisai Co., Ltd.
    • 11.2.3.1. Overview
    • 11.2.3.2. Product
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. Johnson & Johnson
    • 11.2.4.1. Overview
    • 11.2.4.2. Product
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Daiichi Sankyo, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Product
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. Par Pharmaceutical
    • 11.2.6.1. Overview
    • 11.2.6.2. Product
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. Bayer AG
    • 11.2.7.1. Overview
    • 11.2.7.2. Product
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Pfizer Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Product
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. financials (Based on Availability)